← Back to search

Inhibrx Inc

INBX · NASDAQ

Biological Product (except Diagnostic) Manufacturing

Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. Inhibrx has collaborations with bluebird bio, Bristol-Myers Squibb and Chiesi.

ESG Scores

Overall ESG
5.7
Environmental
5.4
Social
4.0
Governance
5.9

Gender Diversity

Female Directors0.4%
Female Executives0.2542372881355932%
CEO GenderMale

Market Data

Price$82.39-5.85 (-6.62%)
Market Cap$1.29B
P/E Ratio
EPS$—
52W High$94.57
52W Low$10.84
Beta2.57